Nilotinib

116 interactions 10 explained in plain English

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Jul 4, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Lefamulin Ketoconazole Topical Doxorubicin Entrectinib Metronidazole Vaginal Oxaliplatin Injection

2 Contraindicated 107 Major 7 Moderate

All (116) Contraindicated (2) Major (107) Moderate (7)

Contraindicated

Nilotinib Ketoconazole Topical Extina® Foam Increased nilotinib exposure, an increased risk of nilotinib-related adverse reactions, an increased ketoconazole exposure and an... Details Nilotinib Lefamulin Xenleta Increased lefamulin exposure, an increased risk of lefamulin-related adverse reactions, an increased sensitive CYP3A4 substrate ex... Details

Major

Nilotinib Acetaminophen And Codeine Capital® & Codeine Explained Increased codeine and morphine exposure Details Nilotinib Abametapir Explained Increased exposure of CYP3A4 substrate Details Nilotinib Omeprazole Gastrobim Explained Reduced nilotinib exposure and reduced efficacy of nilotinib Details Nilotinib Amitriptyline Elavil Explained An increased risk of QT interval prolongation Details Nilotinib Sertraline Explained An increased risk of QT interval prolongation Details Nilotinib Buprenorphine Belbuca Explained An increased risk of QT interval prolongation, increased buprenorphine exposure and an increased risk of buprenorphine-related adv... Details Nilotinib Relugolix Orgovyx Explained Increased risk of QT interval prolongation Details Nilotinib Colchicine Colcrys Explained Increased colchicine exposure and an increased risk of fatal toxicity Details Nilotinib Acalabrutinib Calquence Increased acalabrutinib exposure and increased risk of toxicity Details Nilotinib Amisulpride Injection Barhemsys Increased risk of serious ventricular arrhythmias such as torsades de pointes Details Nilotinib Arsenic Trioxide Trisenox An increased risk of QT interval prolongation Details Nilotinib Aripiprazole Injection Abilify An increased risk of QT interval prolongation Details Nilotinib Arsenic Trioxide Injection Trisenox An increased risk of QT interval prolongation Details Nilotinib Asciminib Scemblix Increased CYP3A4 exposure and an increased risk of CYP3A4-related adverse reactions Details Nilotinib Asenapine Transdermal Patch Secuado An increased risk of QT interval prolongation Details Nilotinib Avapritinib Ayvakit Increased avapritinib exposure and an increased risk of the incidence and severity of adverse reactions Details Nilotinib Azithromycin AzaSite An increased risk of QT interval prolongation Details Nilotinib Cariprazine Vraylar Explained Increased cariprazine and its major active metabolite (didesmethylcariprazine (DDCAR)) exposure Details Nilotinib Alfuzosin UroXatral An increased risk of QT interval prolongation Details Nilotinib Amlodipine Amvaz® Increased amLODIPine exposure and an increased risk of hypotension and edema Details Nilotinib Anagrelide Agrylin Increased risk of QT interval prolongation Details Nilotinib Bedaquiline Sirturo An increased risk of QT interval prolongation Details Nilotinib Bosutinib Bosulif Increased bosutinib exposure Details Nilotinib Brexpiprazole Rexulti Increased brexpiprazole exposure Details Nilotinib Brigatinib Alunbrig Increased brigatinib exposure Details Nilotinib Budesonide Entocort Increased budesonide exposure Details Nilotinib Budesonide Nasal Spray Rhinocort Increased budesonide exposure Details Nilotinib Budesonide Oral Inhalation Pulmicort Increased budesonide exposure Details Nilotinib Captopril Capoten® Increased exposure of nilotinib Details Nilotinib Chloroquine Aralen® An increased risk of QT interval prolongation Details Nilotinib Cyclophosphamide Cytoxan® Decreased cyclophosphamide efficacy Details Nilotinib Cyclophosphamide Injection Cytoxan® Injection Decreased cyclophosphamide efficacy Details Nilotinib Dasatinib Phyrago An increased risk of QT interval prolongation Details Nilotinib Deflazacort Emflaza Increased exposure to active metabolite of deflazacort Details Nilotinib Degarelix Injection Firmagon Increased risk of QT interval prolongation Details Nilotinib Deutetrabenazine Austedo An increased risk of QT interval prolongation Details Nilotinib Dexamethasone Injection Decadron Increased dexamethasone exposure; decreased nilotinib exposure Details Nilotinib Dexamethasone Ophthalmic Dexacidin® (as a combination product containing Dexamethasone, Neomycin, Polymyxin B) Increased dexamethasone exposure; decreased nilotinib exposure Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.